The biotech inflection point, and why it’s a ‘grand final’ for Paradigm Biopharma in CY26
The crucial junction in Phase Three trials is exactly where we find Paradigm Biopharmaceuticals as the…
| Thu, 19 Mar | Close | Change |
| 4:10pm | 8,497.8 | 143 |
| Closed at Thu, 19 Mar 8:05pm | ||
| S&P/ASX Sm. Ords. | 3,317.8 | 113 | 3.30% |
| All Ordinaries | 8,690.7 | 157 | 1.77% |
| S&P/ASX 100 | 7,118.2 | 109 | 1.50% |
| CQT | CONNEQT HEALTH LIMITED | 3.6¢ | 28.6% |
| RAC | RACURA ONCOLOGY LTD | $2.92 | 22.7% |
| MCM | MC MINING LIMITED | 31.5¢ | 18.9% |
| BEL | BENTLEY CAPITAL LIMITED | 1.6¢ | 30.4% |
| LPM | LITHIUM PLUS MINERALS LTD. | 10.0¢ | 23.1% |
| TZL | TZ LIMITED | 3.0¢ | 23.1% |